LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

LLY

1,085.5

+1.29%↑

JNJ

232.04

+0.69%↑

ABBV

214.86

+1.09%↑

UNH

382.38

+0.69%↑

AZN

186.54

-0.37%↓

Kodu・Aktsiate loetelu・Simulations Plus Inc

Simulations Plus Inc

Avatud

SektorTervishoid

15.42 -0.13

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

15.05

Max

15.76

Põhinäitajad
By Trading Economics
Sissetulek	3.9M 4.5M
Müük	5.9M 24M
Aktsiakasum	0.35
Dividenditootlus	0.48
Kasumimarginaal	18.669
Töötajad	212
EBITDA	4.9M 7.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+4.1% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.48% 2.39%
Järgmine tulemuste avaldamine	13. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	27M 278M
Eelmine avamishind	15.55
Eelmine sulgemishind	15.42

Uudiste sentiment

By Acuity

19%

81%

26 / 344 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. mai 2026, 16:52 UTC

Uudisväärsed sündmused

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q Rev $1.76B >SQM

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q EPS $1.28 >SQM

26. mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q EPS $11.61 >WEBC

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q Sales $179.6M >WEBC

26. mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26. mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26. mai 2026, 20:58 UTC

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26. mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26. mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26. mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26. mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26. mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26. mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26. mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26. mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26. mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26. mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

26. mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26. mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26. mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

4.1% tõus

12 kuu keskmine prognoos

Keskmine 16 USD 4.1%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Simulations Plus Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

26 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.